Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin

Urology

Volumn 51, Issue 2, 1998, Pages 226-231

  Sarosdy, Michael F ^a   Manyak, Michael J ^a   Sagalowsky, Arthur I ^a   Belldegrun, Arie ^a   Benson, Mitchell C ^a   Bihrle, William ^a   Carroll, Peter R ^a   Ellis, William J ^a   Hudson, M'Liss A ^a   Sharkey, Francis E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BROPIRIMINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CARCINOMA IN SITU; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; BCG VACCINE; CARCINOMA IN SITU; CYTOSINE; HUMANS; REMISSION INDUCTION; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 0032007334     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00510-4     Document Type: Article

References (19)

1. Farrow GM, Utz DC, Rife CC. Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res. 36:1976;2495-??? (7 Pt 2).
2. Surveillance, initial assessment, and subsequent progress of patients with superficial bladder cancer in a prospective longitudinal study. Cancer Res. 37:1977;2907-2910. (8 Pt 2).
3. Utz DC, Farrow GM. Carcinoma in situ of the urinary tract. Urol Clin North Am. 11:1984;735-740.
4. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med. 325:1991;1205-1209.
5. Morales A, Nickel JC, Wilson JWL. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol. 147:1992;1256-1258.
6. Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol. 152:1994;367-373.
7. Sarosdy MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA. Phase I trial of oral bropirimine in superficial bladder cancer. J Urol. 147:1992;31-33.
8. Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham SD Jr, Grossman HB, See WA, Peabody JO, Moon RD, Flanigan RC, Crawford ED, Morganroth J. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology. 48:1996;21-27.
9. Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lerner SP, Koch MO, Schellhammer PF. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 48:1996;28-32.
10. Lamm DL, Blumenstein B, Sarosdy MF, Grossman HB, Crawford ED. Significant long-term patient benefit with BCG maintenance therapy: a Southwest Oncology Group study. J Urol. 157:1997;213A.
11. Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol. 14:1987;1-12. (suppl 2).
12. Sharkey FE, Sarosdy MF. The significance of central pathology review in clinical studies of transitional cell carcinoma in situ. J Urol. 157:1997;68-70.
13. Grigor KM, Bollina PR. Interpathologist variation in the assessment of G3PT1 bladder carcinoma. Eur Urol. 30:1996;229. (suppl 2).
14. Mazerolles C, Billerey C, Bellot J, Berger N, Boccon-Gibod L, Bougaran J, Dauge MC, Delcourt A, Deslignieres S, De Fromont M, Lesourd A, Viellefond A, Zerat L. Interpathologist variations in grade and stage assessment of bladder tumours. Eur Urol. 30:1996;229. (suppl 2).
15. Bui TT, Schellhammer PF. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology. 49:1997;687-690.
16. Lamm DL. Carcinoma in situ. Urol Clin North Am. 19:1992;499-508.
17. Glashan R. A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. J Urol. 144:1990;658-661.
18. Williams RD, Gleason DM, Smith AY, Zinner NR, Sagalowsky AI, Montie JE, Brosman SA, Marks LS, Brito G, Boxer RJ, Blank BH, Neri R, Rudeen J. Pilot study of intravesical alfa-2b interferon for treatment of bladder carcinoma in situ following BCG failure. J Urol. 155:1996;494A.
19. Manyak MJ. Photodynamic therapy for urologic malignancies. Urol Clin North Am. 19:1992;581-589.